Clinical characteristics and outcomes of patients with VOD
Patient . | Age, y/sex . | Status at conditioning . | GO exposure . | Clinical features . | Biopsy proven . | Defibrotide therapy . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 51/F | Active relapse | Yes (relapse) | Elevated bilirubin; RUQ pain; weight gain | No | No | Died of leukemia |
| 2 | 45/M | 1st CR | No | Elevated bilirubin; RUQ pain; weight gain; MOF | Yes | Yes | Died of VOD/MOF |
| 3 | 20/M | Active relapse | Yes (induction) | Elevated bilirubin; RUQ pain; weight gain; reversal of portal flow on US; MOF | Yes | Yes | Alive; recovered |
| 4 | 45/M | 1st CR | Yes (induction) | Elevated bilirubin, weight gain; MOF | Yes | Yes | Alive; recovered |
| 5 | 19/F | Active relapse | Yes (relapse) | Elevated bilirubin; hepatomegaly; RUQ pain; weight gain | No | No | Died of leukemia |
| 6 | 45/F | 2nd CR | Yes (relapse) | Elevated bilirubin; RUQ pain; MOF | Yes | Yes | Died of VOD/MOF |
| 7 | 48/M | Primary refractory | No | Elevated bilirubin; hepatomegaly; RUQ pain; weight change; reversal of portal flow on US; MOF | Yes | Yes | Died of VOD/MOF |
| 8 | 47/F | 1st CR | Yes (induction) | Elevated bilirubin; hepatomegaly; RUQ pain; weight change; reversal of portal flow on US; MOF | Yes | Yes | Died of VOD/MOF |
| 9 | 43/M | Primary refractory | Yes (relapse) | Elevated bilirubin; RUQ pain; weight change; reversal of portal flow on US; MOF | No | Yes | Died of VOD/MOF |
| 10 | 42/F | 2nd CR | Yes (relapse) | Elevated bilirubin; hepatomegaly; RUQ pain; weight gain; MOF | Yes | Yes | Died of GVHD |
| 11 | 24/F | Primary refractory | No | Elevated bilirubin; RUQ pain, Weight gain | Yes | No | Died of diffuse |
| alveolar | |||||||
| hemorrhage | |||||||
| 12 | 43/M | 1st CR | Yes (induction) | Hepatomegaly; ascites; RUQ pain; weight change; reversal of flow on US; MOF | Yes | Yes | Alive; recovered |
| 13 | 47/M | 1st CR | No | Elevated bilirubin; hepatomegaly; RUQ pain; reversal of flow on US; MOF | Yes | Yes | Died of VOD/MOF |
Patient . | Age, y/sex . | Status at conditioning . | GO exposure . | Clinical features . | Biopsy proven . | Defibrotide therapy . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 51/F | Active relapse | Yes (relapse) | Elevated bilirubin; RUQ pain; weight gain | No | No | Died of leukemia |
| 2 | 45/M | 1st CR | No | Elevated bilirubin; RUQ pain; weight gain; MOF | Yes | Yes | Died of VOD/MOF |
| 3 | 20/M | Active relapse | Yes (induction) | Elevated bilirubin; RUQ pain; weight gain; reversal of portal flow on US; MOF | Yes | Yes | Alive; recovered |
| 4 | 45/M | 1st CR | Yes (induction) | Elevated bilirubin, weight gain; MOF | Yes | Yes | Alive; recovered |
| 5 | 19/F | Active relapse | Yes (relapse) | Elevated bilirubin; hepatomegaly; RUQ pain; weight gain | No | No | Died of leukemia |
| 6 | 45/F | 2nd CR | Yes (relapse) | Elevated bilirubin; RUQ pain; MOF | Yes | Yes | Died of VOD/MOF |
| 7 | 48/M | Primary refractory | No | Elevated bilirubin; hepatomegaly; RUQ pain; weight change; reversal of portal flow on US; MOF | Yes | Yes | Died of VOD/MOF |
| 8 | 47/F | 1st CR | Yes (induction) | Elevated bilirubin; hepatomegaly; RUQ pain; weight change; reversal of portal flow on US; MOF | Yes | Yes | Died of VOD/MOF |
| 9 | 43/M | Primary refractory | Yes (relapse) | Elevated bilirubin; RUQ pain; weight change; reversal of portal flow on US; MOF | No | Yes | Died of VOD/MOF |
| 10 | 42/F | 2nd CR | Yes (relapse) | Elevated bilirubin; hepatomegaly; RUQ pain; weight gain; MOF | Yes | Yes | Died of GVHD |
| 11 | 24/F | Primary refractory | No | Elevated bilirubin; RUQ pain, Weight gain | Yes | No | Died of diffuse |
| alveolar | |||||||
| hemorrhage | |||||||
| 12 | 43/M | 1st CR | Yes (induction) | Hepatomegaly; ascites; RUQ pain; weight change; reversal of flow on US; MOF | Yes | Yes | Alive; recovered |
| 13 | 47/M | 1st CR | No | Elevated bilirubin; hepatomegaly; RUQ pain; reversal of flow on US; MOF | Yes | Yes | Died of VOD/MOF |
Elevated bilirubin indicates > 2 mg/dL of baseline; RUQ, right upper quadrant; weight gain, > 5% of baseline; MOF, multiorgan failure; and US, ultrasound/Doppler.